Posted On: 08/14/2014 8:26:52 PM
Post# of 273254
Arrowhead Research Corp (ARWR) 14.44 $ARWR
Nasdaq stocks posting largest percentage increases
AP - Thu Aug 14, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
'Mad Money' Lightning Round: Don't Buy IBM Right Now
at The Street - Thu Aug 14, 5:00AM CDT
Cramer says he's avoiding Potbelly but likes Opko Health and Hawaiian Holdings.
Jim Cramer's 'Mad Money' Recap: Now That's More Like It
at The Street - Wed Aug 13, 7:25PM CDT
When the consensus changes, the buyers change, too, and that's why Tuesday's stocks were being bought Wednesday, Cramer says.
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - ZACKS - Wed Aug 13, 2:06AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
SmarTrend Watching for Potential Pullback in Shares of Arrowhead Research After 1.17% Gain
Comtex SmarTrend(R) - Tue Aug 12, 4:14PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.70 to a high of $13.71. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $13.50 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Arrowhead Discloses First Human Hepatitis B Therapy Results
at The Street - Tue Aug 12, 4:11PM CDT
The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.
Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520
Business Wire - Tue Aug 12, 4:01PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an update on the Phase 2a study of ARC-520, its RNAi-based candidate for the treatment of chronic hepatitis B infection. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. Conference call and webcast details can be found below.
Arrowhead Research Set to Possibly Rebound After Yesterday's Selloff of 1.84%
Comtex SmarTrend(R) - Mon Aug 04, 5:31PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $11.46 to a high of $12.38. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $11.75 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Technical Data on Biotech Stocks -- Arrowhead Research, Celldex Therapeutics, Synthetic Biologics, StemCells, and Sarepta Therapeutics
PR Newswire - Mon Aug 04, 7:50AM CDT
On Friday, August 01, 2014, the NASDAQ Composite ended at 4,352.64, down 0.39%, the Dow Jones Industrial Average finished the day 0.42% lower at 16,493.37, and the S&P 500 closed at 1,925.15, down 0.29%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.19, down 0.03%, and the index has declined 2.38% in the last one month. Investor-Edge has initiated coverage on the following equities: Arrowhead Research Corporation (NASDAQ: ARWR), Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), StemCells Inc. (NASDAQ: STEM), and Sarepta Therapeutics Inc. (NASDAQ: SRPT). Free research on these five companies can be accessed at:
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results
Business Wire - Thu Jul 31, 3:06PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 third quarter ended June 30, 2014, on Tuesday, August 12, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 82825377. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations.
'Fast Money' Recap: Playing China Through U.S. Stocks
at The Street - Tue Jul 29, 4:00AM CDT
The trading panel looked at the Shanghai composite index and how investors can use U.S. stocks as a proxy.
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 21, 12:45PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead
PR Newswire - Fri Jul 18, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Exelixis, Inc. (NASDAQ: EXEL), InterMune Inc. (NASDAQ: ITMN), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4874-100free.
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Why AeroVironment, America Movil, and Arrowhead Research Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 09, 4:15PM CDT
Unlike the previous two days, it was a notably exciting day for economic data releases, which helped push the broad-based S&P 500 higher, and put an end to its two-day losing streak. No piece of data was more awaited than the release of...
Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Jul 09, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Nasdaq stocks posting largest percentage increases
AP - Thu Aug 14, 12:17PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
'Mad Money' Lightning Round: Don't Buy IBM Right Now
at The Street - Thu Aug 14, 5:00AM CDT
Cramer says he's avoiding Potbelly but likes Opko Health and Hawaiian Holdings.
Jim Cramer's 'Mad Money' Recap: Now That's More Like It
at The Street - Wed Aug 13, 7:25PM CDT
When the consensus changes, the buyers change, too, and that's why Tuesday's stocks were being bought Wednesday, Cramer says.
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - ZACKS - Wed Aug 13, 2:06AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
SmarTrend Watching for Potential Pullback in Shares of Arrowhead Research After 1.17% Gain
Comtex SmarTrend(R) - Tue Aug 12, 4:14PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.70 to a high of $13.71. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $13.50 on volume of 6.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Arrowhead Discloses First Human Hepatitis B Therapy Results
at The Street - Tue Aug 12, 4:11PM CDT
The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.
Arrowhead Reports Fiscal 2014 Third Quarter Financial Results and Provides Update on ARC-520
Business Wire - Tue Aug 12, 4:01PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 third quarter ended June 30, 2014 and provided an update on the Phase 2a study of ARC-520, its RNAi-based candidate for the treatment of chronic hepatitis B infection. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. Conference call and webcast details can be found below.
Arrowhead Research Set to Possibly Rebound After Yesterday's Selloff of 1.84%
Comtex SmarTrend(R) - Mon Aug 04, 5:31PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $11.46 to a high of $12.38. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $11.75 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Technical Data on Biotech Stocks -- Arrowhead Research, Celldex Therapeutics, Synthetic Biologics, StemCells, and Sarepta Therapeutics
PR Newswire - Mon Aug 04, 7:50AM CDT
On Friday, August 01, 2014, the NASDAQ Composite ended at 4,352.64, down 0.39%, the Dow Jones Industrial Average finished the day 0.42% lower at 16,493.37, and the S&P 500 closed at 1,925.15, down 0.29%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 704.19, down 0.03%, and the index has declined 2.38% in the last one month. Investor-Edge has initiated coverage on the following equities: Arrowhead Research Corporation (NASDAQ: ARWR), Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), StemCells Inc. (NASDAQ: STEM), and Sarepta Therapeutics Inc. (NASDAQ: SRPT). Free research on these five companies can be accessed at:
Biotech Stock Mailbag: Arrowhead, Catalyst Pharma
at The Street - Fri Aug 01, 7:06AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Arrowhead to Report Fiscal 2014 Third Quarter Financial Results
Business Wire - Thu Jul 31, 3:06PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 third quarter ended June 30, 2014, on Tuesday, August 12, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 82825377. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations.
'Fast Money' Recap: Playing China Through U.S. Stocks
at The Street - Tue Jul 29, 4:00AM CDT
The trading panel looked at the Shanghai composite index and how investors can use U.S. stocks as a proxy.
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 21, 12:45PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead
PR Newswire - Fri Jul 18, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Exelixis, Inc. (NASDAQ: EXEL), InterMune Inc. (NASDAQ: ITMN), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4874-100free.
14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Why AeroVironment, America Movil, and Arrowhead Research Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 09, 4:15PM CDT
Unlike the previous two days, it was a notably exciting day for economic data releases, which helped push the broad-based S&P 500 higher, and put an end to its two-day losing streak. No piece of data was more awaited than the release of...
Trade-Ideas: Arrowhead Research (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Jul 09, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate
(0)
(0)Scroll down for more posts ▼
